Ingmar Bruns insider trades: Zentalis Pharmaceuticals (ZNTL) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Ingmar reports to the SEC
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Feb 9, 2026 | ZNTL | ↓ Sell | 3,297 | $2.43 | $8K | Direct | Feb 10, 2026 (1d) |
| Feb 6, 2025 | ZNTL | ↑ Buy | 20,000 | $2.28 | $46K | Direct | Feb 12, 2025 (6d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ZNTL insiders
Open-market trades in the last 12 months
About Ingmar Bruns's insider trades
Ingmar Bruns is Chief Medical Officer at Zentalis Pharmaceuticals (ZNTL). Since Feb 6, 2025, Ingmar has reported 1 open-market purchase worth $46K and 1 sale worth $8K on SEC Form 4. In the last 12 months: 1 sale ($8K).
Their filings also include grants and awards (4 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ZNTL insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.